NASPANVAC

Nasal Pandemic Influenza Vaccine

Coordinatore	ARCHIMEDES DEVELOPMENT LIMITED    more  Organization address address: Albert Einstein Centre Nottingham Science and Technology Park city: Nottingham postcode: NG7 2TN contact info Titolo: Mr. Nome: Anthony Cognome: Rhodes Email: send email Telefono: +44115 9078704 Fax: 441159000000
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	4˙971˙768 €
EC contributo	3˙573˙648 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-A
Funding Scheme	CP-FP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-05-01   -   2012-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ARCHIMEDES DEVELOPMENT LIMITED  Organization address address: Albert Einstein Centre Nottingham Science and Technology Park city: Nottingham postcode: NG7 2TN contact info Titolo: Mr. Nome: Anthony Cognome: Rhodes Email: send email Telefono: +44115 9078704 Fax: 441159000000	UK (Nottingham)	coordinator	0.00
2	EVICOM LTD  Organization address address: "Lyndhurst Road, Ascentia House" city: ASCOT postcode: SL5 9ED contact info Titolo: Dr. Nome: Alastair Cognome: Knight Email: send email Telefono: +44 208 891 1848 Fax: +44 208 891 4800	UK (ASCOT)	participant	0.00
3	HEALTH PROTECTION AGENCY HPA  Organization address address: Central Office - 7th Floor, Holborn Gate - High Holborn 330 city: LONDON postcode: WC1V 7PP contact info Titolo: Ms. Nome: Amanda Cognome: King Email: send email Telefono: +44 1 707641000 Fax: +44 1 707641366	UK (LONDON)	participant	0.00
4	RETROSCREEN VIROLOGY LTD  Organization address address: NEW ROAD QUEEN MARY BIOENTERPRISE INNOVATION CENTRE 42 city: LONDON postcode: E1 2AX contact info Titolo: Prof. Nome: John Cognome: Oxford Email: send email Telefono: 442087000000 Fax: 442087000000	UK (LONDON)	participant	0.00
5	THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN  Organization address address: College Green - city: DUBLIN postcode: 2 contact info Titolo: Ms. Nome: Deirdre Cognome: Savage Email: send email Telefono: +353 1 8961942 Fax: +353 1 6772237	IE (DUBLIN)	participant	0.00
6	UNIVERSITA' DEGLI STUDI DI SIENA  Organization address address: VIA BANCHI DI SOTTO 55 city: SIENA postcode: 53100 contact info Titolo: Prof. Nome: Silvano Cognome: Focardi Email: send email Telefono: +39 0577 232206 Fax: +39 0577 232202	IT (SIENA)	participant	0.00
7	UNIVERSITETET I BERGEN  Organization address address: Museplassen 1 city: BERGEN postcode: 5007 contact info Titolo: Ms. Nome: Inger Cognome: Gjesdahl Email: send email Telefono: +47 5 5584998 Fax: +47 5 5584991	NO (BERGEN)	participant	0.00
8	UNIVERSITY OF LEICESTER  Organization address address: University Road city: LEICESTER postcode: LE1 7RH contact info Titolo: Ms. Nome: Marie Cognome: Singer Email: send email Telefono: +44 116 223 1799 Fax: +44 116 252 2028	UK (LEICESTER)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The project is being undertaken in response to the need to develop an effective, user friendly, heat stable vaccine to control the highly pathogenic form of avian influenza virus (H5 and H7 subtypes) which has the potential to cause another global influenza pandemic. The overall objective of this programme is to develop a nasal avian influenza vaccine using ChiSys® (chitosan), which is a chitosan-based technology of Archimedes Development Ltd.. Chitosan has already been tested with several nasally delivered antigens pre-clinically and clinically with excellent results. The most effective way of controlling a pandemic flu would be via the nasal route as this route is advantaged to generate both systemic and mucosal antibodies; the latter allowing virus control at its point of entry. In comparison the currently used injection route cannot achieve the mucosal response. Intranasal vaccination has further advantages: avoids the need for injection and safe disposal of syringes, eliminate the risk of HIV transmission through re-use or accidental contact with body fluids, have greater public compliance and well-suited to rapid mass global vaccination programmes. The scientific objectives of the project are: induce both systemic and mucosal immunity, evaluation of efficacy and toxicity in preclinical studies, evaluation of efficacy and safety profile in humans, provide a substantial level of cross-immunity against a drifted strains of H5 or H7, effective at low dose to meet the global demands from limited vaccine stockpiles, thermal stability so as to avoid refrigeration for storage and transportation and user friendly vaccine applicator. The consortium members have extensive experience in their specialist fields which would enable the success of this project. ChiSys® would be an excellent candidate for developing an intranasal pandemic influenza vaccine to provide a quantum leap in successfully combating pandemic influenza globally.'